Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1)

British Journal of Pharmacology

Volumn 172, Issue 2, 2015, Pages 349-363

  Knapman, Alisa ^a   Connor, Mark ^a  

^a MACQUARIE UNIVERSITY   (Australia)

Author keywords

A118G; addiction; analgesia; dependence; pharmacogenomics; tolerance

Indexed keywords

MU OPIATE RECEPTOR; MU OPIATE RECEPTOR 1; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; BINDING AFFINITY; DNA CONFORMATION; GENE EXPRESSION; GENE FUNCTION; GENETIC VARIABILITY; HUMAN; IN VITRO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; OPRM1 GENE; RECEPTOR BINDING; RECEPTOR GENE; REVIEW; SECOND MESSENGER; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ACTIVITY RELATION; ANIMAL; CHEMISTRY; GENETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, OPIOID, MU; SIGNAL TRANSDUCTION;

EID: 84906824182     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12644     Document Type: Review

References (114)

1. Abrol R, Kim SK, Bray JK, Trzaskowski B, Goddard WA 3rd, (2013). Conformational ensemble view of G protein-coupled receptors and the effect of mutations and ligand binding. Methods Enzymol 520: 31-48.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G-protein couple receptors. Br J Pharmacol 170: 1459-1581.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, Peters JA, Harmar AJ, and CGTP Collaborators (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Ion channels. Br J Pharmacol 170: 1607-1651.
4. Atwood BK, Lopez J, Wager-Miller J, Mackie K, Straiker A, (2012). Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis. BMC Genomics 12: 14.
5. Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T, Vogel Z, (1996). Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvment of Gβγ. J Biol Chem 271: 21309-21315.
6. Bailey CP, Oldfield S, Llorente J, Caunt CJ, Teschemacher AG, Roberts L, et al. (2009). Involvement of PKC alpha and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of mu-opioid receptors in mature brain neurons. Br J Pharmacol 158: 157-164.
7. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL, (2001). A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem 276: 3130-3137.
8. Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Goldman D, (1997). μ-opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry 2: 490-494.
9. Berrettini WH, Hoehe MR, Ferraro TN, DeMaria PA, Gottheil E, (1997). Human mu-opioid receptor gene polymorphisms and vulnerability to substance abuse. Addict Biol 2: 303-308.
10. Beyer A, Koch T, Schroder H, Schulz S, Hollt V, (2004). Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization and resensitization of the human mu-opioid receptor. J Neurochem 89: 553-560.
11. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, et al. (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci USA 95: 9608-9613.
12. Borgland SL, Connor M, Osborne PB, Furness JB, Christie MJ, (2003). Opioid agonists have different efficacy profiles for G protein activation, rapid desensitization, and endocytosis of mu-opioid receptors. J Biol Chem 278: 18776-18784.
13. Capeyrou R, Riond J, Corbani M, Lepage JF, Bertin B, Emorine LJ, (1997). Agonist-induced signaling and trafficking of the μ-opioid receptor: role of serine and threonine residues in the third cytoplasmic loop and C-terminal domain. FEBS Lett 415: 200-205.
14. Cawston EE, Redmond WJ, Breen C, Grimsey N, Connor M, Glass M, (2013). Real-time characterisation of cannabinoid receptor 1 (CB1) allosteric modulators reveals novel mechanism of action. Br J Pharmacol 170: 893-907.
15. Celver J, Xu M, Jin W, Lowe J, Chavkin C, (2004). Distinct domains of the mu-opioid receptor control uncoupling and internalization. Mol Pharmacol 65: 528-537.
16. Celver JP, Lowe J, Kovoor A, Gurevich VV, Chavkin C, (2001). Threonin 180 is required for G-protein-coupled receptor kinase 3- and beta-arrestin 2-mediated desensitization of the mu-opioid receptor in Xenopus oocytes. J Biol Chem 276: 4894-4900.
17. Chaipatikul V, Loh HH, Law PY, (2003). Ligand-selective activation of μ-opioid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain. J Pharmacol Exp Ther 305: 909-918.
18. Charfi I, Nagi K, Mnie-Filali O, Thibault D, Balboni G, Schiller PW, et al. (2013). Ligand- and cell-dependent determinants of internalization and cAMP modulation by delta opioid receptor (DOR) agonists. Cell Mol Life Sci. doi: 10.1007/s00018-013-1461-7.
19. Chavkin C, McLaughlin JP, Celver JP, (2001). Regulation of opioid receptor function by chronic agonist exposure: constitutive activity and desensitization. Mol Pharmacol 60: 20-25.
20. Chen Y, Chen C, Wang Y, Liu-Chen LY, (2006). Ligands regulate cell surface level of the human kappa opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists. J Pharmacol Exp Ther 319: 765-775.
21. Clayton CC, Bruchas MR, Lee ML, Chavkin C, (2010). Phosphorylation of the μ-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy. Mol Pharmacol 77: 339-347.
22. Comptom P, Geschwind DH, Alarcon M, (2003). Association between human mu-opioid receptor gene polymorphism, pain tolerance, and opioid addiction. Am J Med Genet B Neuropsychiatr Genet 121B: 76-82.
23. Connor M, Christie MD, (1999). Opioid receptor signaling mechanisms. Clin Exp Pharmacol Physiol 26: 493-499.
24. Connor M, Osborne PB, Christie MJ, (2004). Mu-opioid receptor desensitization: is morphine different? Br J Pharmacol 143: 685-696.
25. Cooke AE, Oldfield S, Krasel C, Mundell SJ, Henderson G, Kelly E, (2014). Morphine-induced internalization of the L83I mutant of the rat μ-opioid receptor. Brit J Pharmacol in press.
26. Corbett AD, Henderson G, McKnight AT, Paterson SJ, (2006). 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 147 (Suppl. 1): S153-S162.
27. Cox B, (2013). Recent developments in the study of opioid receptors. Mol Pharmacol 83: 723-728.
28. Crowley JJ, Oslin DW, Patkar AA, Gottheil E, DeMaria PA Jr, O'Brien CP, et al. (2003). A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet 13: 169-173.
29. Crystal HA, Hamon S, Randesi M, Cook J, Anastos K, Lazar J, (2012). A C17T polymorphism in the mu opiate receptor is associated with quantitative measures of drug use in African American women. Addict Biol 17: 181-191.
30. Dahan A, Aarts L, Smith TW, (2010). Incidence, reversal and prevention of opioid-induced respiratory depression. Anesthesiology 112: 226-238.
31. Dang VC, Christie MJ, (2012). Mechanisms of rapid opioid receptor desensitization, resensitization and tolerance in brain neurons. Br J Pharmacol 165: 1704-1716.
32. Deb I, Chakraborty J, Gangopadhyay PK, Choudhury SR, Das S, (2010). Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. J Neurochem 112: 486-496.
33. Dhalla IA, Persaud N, Juurlink DN, (2011). Facing up to the prescription opioid crisis. BMJ 343: d5142.
34. Diatchenko L, Robinson JE, Maixner W, (2011). Elucidation of mu-opioid gene structure: how genetics can help predict therapeutic response to opioids. Eur J Pain Suppl 5: 433-448.
35. Doll C, Konietzko J, Poll F, Koch T, Hollt V, Schulz S, (2011). Agonist-selective patterns of mu-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol 164: 298-307.
36. Doll C, Poll F, Peuker K, Loktev A, Gluck L, Schulz S, (2012). Deciphering μ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells. Br J Pharmacol 167: 1259-1270.
37. El Kouhen R, Burd AL, Erickson-Herbrandson LJ, Chang CY, Law PY, Loh HH, (2001). Phosphorylation of Ser363, Thr370 and Ser375 residues within the carboxyl tail differentially regulates μ-opioid receptor internalization. J Biol Chem 276: 12774-12780.
38. Fortin JP, Ci L, Schroeder J, Goldstein C, Montefusco MC, Peter I, et al. (2010). The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs. Mol Pharmacol 78: 837-845.
39. Georgoussi Z, Merkouris M, Mullaney I, Megaritis G, Carr C, Zioudrou C, et al. (1997). Selective interactions of mu-opioid receptors with Pertussis toxin-sensitive G proteins: involvement of the third intracellular loop and the c-terminal tail in coupling. Biochim Biophys Acta 1359: 263-274.
40. Goldfeld DA, Zhu K, Beuming T, Friesner RA, (2011). Successful prediction of the intra- and extracellular loops of four G-protein coupled receptors. Proc Natl Acad Sci USA 109: 9665-9671.
41. Grecksch G, Just S, Pierstorff C, Imhof AK, Gluck L, Doll C, et al. (2011). Analgesic tolerance to high-efficacy agonists but not to morphine is diminished in phosphorylation-deficient S375A mu-opioid receptor knock-in mice. J Neurosci 31: 13890-13896.
42. Hoehe MR, Kopke K, Wendel B, Rohde K, Flachmeier C, Kidd KK, et al. (2000). Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 9: 2895-2908.
43. Huang P, Chen C, Mague SD, Blendy JA, Liu-Chen LY, (2012). A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability. Biochem J 441: 379-386.
44. Ikeda K, Ide S, Han W, Hayashida M, Uhl GR, Sora I, (2005). How individual sensitivity to opiates can be predicted by gene analyses. Trend Pharmacol Sci 26: 311-317.
45. Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, (2006). Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol 70: 676-685.
46. Jordan B, Devi LA, (1998). Molecular mechanisms of opioid receptor signal transduction. Br J Anaesth 81: 12-19.
47. Kapur S, Sharad S, Singh RA, Gupta AK, (2007). A118G polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin. J Integr Neurosci 6: 511-522.
48. Kazius J, Wurdinger K, van Iterson M, Kok J, Back T, Ijzerman AP, (2008). GPCR NaVa database: natural variants in human G protein-coupled receptors. Hum Mut 29: 39-44.
49. Kelly E, Bailey CP, Henderson G, (2008). Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol 153 (Suppl. 1): S379-S388.
50. Kelly E, (2013). Efficacy and ligand bias at the μ-opioid receptor. Br J Pharmacol 169: 1430-1446.
51. Kenakin T, (2002). Efficacy at G-protein-coupled receptors. Nat Rev Drug Discov 1: 103-110.
52. Kenakin T, Christopoulos A, (2013). Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12: 205-216.
53. Kenakin T, Miller LJ, (2010). Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol Rev 62: 265-304.
54. Knapman A, Santiago M, Du Y-P, Bennallack P, Christie MJ, Connor M, (2013). A continuous, fluorescence based assay of μ-opioid receptor activation in AtT-20 cells. J Biomol Screen 18: 269-276.
55. Knapman A, Abogadie F, McIntrye P, Connor M, (2014). A real time, fluorescence-based assay for measuring μ-opioid receptor modulation of adenylyl cyclase activity in Chinese hamster ovary cells. J Biomol Screen, 19: 223-231.
56. Koch T, Hollt V, (2008). Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther 117: 199-206.
57. Koch T, Kroslak T, Averbeck M, Mayer P, Schroder H, Raulf E, et al. (2000). Allelic variation S268P of the human mu-opioid receptor affects both desensitization and G protein coupling. Mol Pharmacol 58: 328-334.
58. Kreek MJ, Bart G, Lilly C, LaForge KS, Nielsen DA, (2005). Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 57: 1-26.
59. Kroslak T, LaForge KS, Gianotti RJ, Ho A, Nielsen DA, Kreek MJ, (2007). The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem 103: 77-87.
60. LaForge KS, Yuferov V, Kreek MJ, (2000). Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol 410: 249-268.
61. Law PY, Wong YH, Loh HH, (2000). Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40: 389-430.
62. Lefkowitz RJ, (1998). G protein couple receptors III. New roles for receptor kinases and β-arrestins in receptor signaling and desensitization. J Biol Chem 273: 18677-18680.
63. Li J, Huang P, Chen C, de Riel JK, Weinstein H, Liu-Chen LY, (2001). Constitutive activation of the mu-opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression. Biochemistry 40: 12039-12050.
64. Lopez Soto EJ, Raingo J, (2012). A118G mu opioid receptor polymorphism increases inhibitory effects on CaV2.2 channels. Neurosci Lett 523: 190-194.
65. Lotsch J, Geisslinger G, (2005). Are μ-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11: 82-89.
66. Mague SD, Blendy JA, (2010). OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend 108: 172-182.
67. Mague SD, Isiegas C, Huang P, Liu-Chen LY, Lerman C, Blendy JA, (2009). Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci USA 106: 10847-10852.
68. Mahmoud S, Thorsell A, Sommer WH, Heilig M, Holgate JK, Bartlett SE, et al. (2011). Pharmacological consequence of the A118G μ opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of Ca2+ channels in humanized mouse sensory neurons. Anesthesiology 115: 1054-1062.
69. Manglik A, Kruse AC, Kobilka TS, Thian FS, Mathiesen JM, Sunahara RK, et al. (2012). Crystal structure of the μ-opioid receptor bound to a morphinan antagonist. Nature 485: 321-326.
70. Margas W, Zubkoff I, Schuler HG, Janicki PK, Ruiz-Velasco V, (2007). Modulation of Ca2+ channels by heterologously expressed wild-type and mutant human μ opioid receptors (hMORs) containing the the A118G single-nucleotide polymorphism. J Neurophysiol 97: 1058-1067.
71. Massotte D, Brillet K, Kieffer BL, Milligan G, (2002). Agonists activate Gi1α or Gi2α fused to the human mu opioid receptor differently. J Neurochem 81: 1372-1382.
72. Matthes HWD, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, et al. (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 383: 819-823.
73. Mazarakou G, Georgoussi Z, (2005). STAT5A interacts with and is phosphorylated upon activation of the mu-opioid receptor. J Neurochem 93: 918-931.
74. Merikangas KR, Stolar M, Stevens DE, Goulet J, Preisig MA, Fenton B, et al. (1998). Familial transmission of substance use disorders. Arch Gen Psychiatry 55: 973-979.
75. Merkouris M, Dragatsis I, Megaritis G, Konidakis G, Zioudrou C, Milligan G, et al. (1996). Identification of the critical domains of the delta-opioid receptor involved in G protein coupling using site-specific synthetic peptides. Mol Pharmacol 50: 985-993.
76. Mizoguchi H, Watanabe C, Sakurada T, Sakurada S, (2012). New vistas in opioid control of pain. Curr Opin Pharmacol 12: 87-91.
77. Moore RA, McQuay HJ, (2005). Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomized trials of oral opioids. Arthritis Res Ther 7: R1046-R1051.
78. Mura E, Govoni S, Racchi M, Carossa V, Ranzani GN, Allegri M, et al. (2013). Consequences of the 118A > G polymorphism in the OPRM1 gene: translation from bench to bedside? J Pain Res 6: 331-353.
79. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. (2010). Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev (1): CD006605.
80. Oertel BG, Kettner M, Scholich K, Renne C, Roskam B, Geisslinger G, et al. (2009). A common human μ-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem 284: 6530-6535.
81. Oertel BG, Doehring A, Roskam B, Kettner M, Hackmann N, Ferreiros N, et al. (2012). Genetic-epigenetic interaction modulates μ-opioid receptor regulation. Hum Mol Genet 21: 4751-4760.
82. Pasternak GW, Pan YX, (2013). Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 65: 1257-1317.
83. Petäjä-Repo UE, Hogue M, Bhalla S, Laperrière A, Morello JP, Bouvier M, (2002). Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation. EMBO J 21: 1628-1637.
84. Pineyro G, Archer-Lahlou E, (2007). Ligand-specific receptor states: implications for opiate receptor signaling and regulation. Cell Signal 19: 8-19.
85. Ramchandani VA, Umhau J, Pavon FJ, Ruiz-Velasco V, Margas W, Sun H, et al. (2011). A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry 16: 809-817.
86. Ravindranathan A, Joslyn G, Robertson M, Schuckit MA, Whistler JL, White RL, (2009). Functional characterization of human variants of the mu-opioid receptor gene. Proc Natl Acad Sci USA 106: 10811-10816.
87. Rivero G, Llorente J, McPherson J, Cooke A, Mundell S, McArdle CA, et al. (2012). Endomorphin 2: a biased agonist at the μ-opioid receptor. Mol Pharmacol 82: 178-188.
88. Rommelspacher H, Smolka M, Schmidt LG, Samochowiec J, Hoehe MR, (2001). Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals. Alcohol 24: 129-135.
89. Saidak Z, Blake-Palmer K, Hay DL, Northup JK, Glass M, (2006). Differential activation of G-proteins by μ-opioid receptor agonists. Br J Pharmacol 147: 671-680.
90. Serohijos AWR, Yin S, Ding F, Gauthier J, Gibson DG, Maixner W, et al. (2011). Structural bias for mu-opioid receptor binding and activation. Structure 19: 1683-1690.
91. Sharma SK, Nirenberg M, Klee WA, (1975). Morphine receptors as regulators of adenylate cyclase activity. Proc Natl Acad Sci USA 72: 590-594.
92. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G, (2002). Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat 19: 459-460.
93. Singh VK, Bajpai K, Biswas S, Haq W, Khan MY, Mathur KB, (1997). Molecular biology of opioid receptors. Neuroimmunomodulation 4: 285-297.
94. Skorpen F, Laugsand EA, (2008). Variable response to opioid treatment: any genetic predictors in sight? Palliat Med 22: 310-327.
95. Tan EC, Tan CH, Karupathivan U, Yap EP, (2003). Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport 14: 569-572.
96. Thompson MD, Percy ME, McIntyre WB, Cole DE, (2008). G protein-coupled receptors disrupted in human genetic disease. Methods Mol Biol 448: 109-137.
97. Tudashki HB, Robertson DN, Schiller PW, Pineyro G, (2014). Endocytic profiles of δ-opioid receptor ligands determine the duration of rapid but not sustained cAMP responses. Mol Pharmacol 85: 148-161.
98. Ueda H, Inoue M, Matsumoto T, (2001). Protein kinase C-mediated inhibition of mu-opioid receptor internalization and its involvement in the development of acute tolerance to peripheral mu-agonist analgesia. J Neurosci 21: 2967-2973.
99. Uhl GR, Sora I, Wang Z, (1999). The mu opiate receptor as a candidate gene for pain: polymorphisms, variations in expression, nociception, and opiate responses. Proc Natl Acad Sci USA 96: 7752-7755.
100. Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM, (2004). Pharmacologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 5: 821-837.
101. Visiers I, Hassan SA, Weinstein H, (2001). Differences in conformational properties of the second intracellular loop (IL2) in 5HT(2C) receptors modified by RNA editing can account for G protein coupling efficiency. Protein Eng 14: 409-414.
102. Walter C, Lotsch J, (2009). Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment. Pain 146: 270-275.
103. Wang D, Sadee W, Quillan JM, (1999). Calmodulin binding to G protein coupling domain of opioid receptors. J Biol Chem 274: 22081-22088.
104. Wang D, Quillan JM, Winans K, Lucas JL, Sadee W, (2001). Single nucleotide polymorphisms in the human μ opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem 276: 34624-34630.
105. Wang HL, (1999). A conserved arginine in the distal third intracellular loop of the mu-opioid receptor is required for G protein activation. J Neurochem 72: 1307-1314.
106. Wang Y, Li JG, Huang P, Xu W, Liu-Chen LY, (2003). Differential effects of agonists on adenylyl cyclase superactivation mediated by the kappa opioid receptors: adenylyl cylcase superactivation is independent of agonist-induced phosphorylation, desensitization, internalization, and down-regulation. J Pharmacol Exp Ther 307: 1127-1134.
107. Wang YJ, Huang P, Ung A, Blendy JA, Liu-Chen LY, (2012). Reduced expression of the μ-opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. Neuroscience 205: 178-184.
108. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M, (1999). Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron 23: 737-746.
109. Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, et al. (2013). Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 65: 223-254.
110. Zhang F, Steinberg SF, (2013). S49G and R389G polymorphisms of the β-adrenergic receptor influence signaling via the cAMP-PKA and ERK pathways. Physiol Genomics 45: 1186-1192.
111. Zhang L, Loh HH, Law PY, (2013). A novel noncanonical signaling pathway for the μ-opioid receptor. Mol Pharmacol 84: 844-853.
112. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W, (2005). Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 280: 32618-32624.
113. Zheng C, Chen L, Chen X, He X, Yang J, Shi Y, et al. (2013). The second intracellular loop of the human cannabinoid CB2 receptor governs G protein coupling in coordination with the carboxyl terminal domain. PLoS ONE 8: e63262.
114. Zheng H, Loh HH, Law PY, (2010). Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications. IUBMB Life 62: 112-119.